HOME > LATEST
LATEST
-
REGULATORY Japan Panel to Discuss Fate of SanBio’s Sakigake Cell Therapy amid Stalled Review
March 19, 2024
-
BUSINESS ASKA Ties Up with Red Arrow on Novel Preeclampsia Treatment
March 19, 2024
-
BUSINESS Canaglu OD Tablet Version Approved in Japan
March 19, 2024
-
BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
-
BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
-
ORGANIZATION Doctors’ Groups Call for Cross-Ministerial Efforts to Spur Genomic Medicine
March 18, 2024
-
ACADEMIA Lecanemab Combo Trial Launched in Japan for Familial Alzheimer’s
March 18, 2024
-
REGULATORY Japan to Cap COVID Vaccine Copay at 7,000 Yen under NIP
March 18, 2024
-
BUSINESS BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
-
BUSINESS Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
-
BUSINESS Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
-
REGULATORY Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
March 18, 2024
-
REGULATORY Another Daiichi Sankyo Veteran to Take Over as Provost of SCARDA
March 15, 2024
-
REGULATORY Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
-
REGULATORY Japan to Set Value-Based Share of 65% as Secondary Target for Generic Use
March 15, 2024
-
BUSINESS Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
March 15, 2024
-
BUSINESS Meiji/KM Biologics’ 5-in-1 Vaccine Now Available Ahead of NIP Rollout
March 15, 2024
-
BUSINESS Ono, Sibylla Strike Neuroscience Drug Discovery Pact
March 15, 2024
-
BUSINESS Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
-
BUSINESS Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
ページ
Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…